SCHEMBL2913632

SCHEMBL2913632

Cc1ccc(-c2cc(CCCO)cc(C(C)(C)C)c2O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS2 Q9H2K2 1/20 0.44
BACE1 P56817 1/20 0.41
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
ALDH1A1 P00352 5/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
MAPK1 P28482 2/20 0.40
GSR P00390 2/20 0.40
HPGD P15428 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40
HTT P42858 1/20 0.40
LMNA P02545 3/20 0.40
TSHR P16473 3/20 0.40
CYP2C9 P11712 3/20 0.40
CYP2C19 P33261 3/20 0.40
CA2 P00918 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
POLB P06746 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2910937 0.87 GAA (0.47) TNKS2BACE1ALDH1A1SMN1; SMN2MAPK1
SCHEMBL2917135 0.86 TNKS2 (0.53) TNKS2BACE1SMN1; SMN2MAPK1HPGD
SCHEMBL2414760 0.81 ALDH1A1 (0.56) TNKS2ALDH1A1SMN1; SMN2MAPK1GSR
Methane SCHEMBL27710180 0.80 ALDH1A1 (0.55) TNKS2ALDH1A1SMN1; SMN2MAPK1GSR
SCHEMBL2916759 0.79 CYP1A2 (0.52) TNKS2ALDH1A1SMN1; SMN2MAPK1GSR
SCHEMBL31707338 0.79 CYP1A2 (0.52) TNKS2ALDH1A1SMN1; SMN2MAPK1GSR
SCHEMBL2413153 0.76 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2MAPK1GSRHPGD
SCHEMBL15065758 0.75 PTGS2 (0.52) PTGS1PTGS2ALDH1A1MAPK1HPGD
SCHEMBL2410411 0.75 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2MAPK1GSRHPGD
SCHEMBL2413923 0.75 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2MAPK1GSRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2110370-B1 Method of producing p-hydroxyphenylalkanols SUMITOMO CHEMICAL CO (JP) 2010-09-01 EP disclosed
EP-1348686-B1 Method of producing p-hydroxyphenylalkanols SUMITOMO CHEMICAL CO (JP) 2010-03-03 EP disclosed
EP-2110370-A1 Method of producing p-hydroxyphenylalkanols Sumitomo Chemical Company, Limited (JP) 2009-10-21 EP disclosed
US-6717020-B2 HIGH YIELD REACTION OF PHENOLS AND UNSATURATED ALCOHOLS IN PRESENCE OF SUCH AS TITANIUM TETRAETHOXIDE AND SODIUM METHOXIDE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2004-04-06 US disclosed
US-20030195379-A1 Method of producing p-Hydroxyphenylalkanols SUMITOMO CHEMICAL COMPANY, LIMITED 2003-10-16 US disclosed
EP-1348686-A1 Method of producing p-hydroxyphenylalkanols SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195379-A1 Method of producing p-Hydroxyphenylalkanols ADH1C, NR1H3, ADH5 TNKS2 3493/4885BACE1 4580/4885PTGS1 397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.